

**PATRICK LEFEBVRE**  
**Managing Principal**

Phone: 514 394 4471  
Fax: 514 394 4461  
patrick.lefebvre@analysisgroup.com

1190 avenue des Canadiens-de-Montréal  
Tour Deloitte, Suite 1500  
Montreal, QC, H3B 0G7

Mr. Lefebvre specializes in the application of biostatistics and economics of health outcomes research. He has conducted and directed numerous studies in pharmacoeconomics, epidemiology, and health outcomes research in a variety of therapeutic areas such as anemia, asthma, cardiovascular diseases, chronic obstructive pulmonary disease, diabetes, genetic syndrome, hematology, hypertension, infectious diseases, myelodysplastic syndromes, neurological disorders, obesity, oncology, renal diseases, respiratory diseases, and women's health. His recent work in the health care sector includes numerous clinical trials and medical claims data analyses to investigate resource utilization patterns, patient-reported quality of life, clinical effectiveness, direct medical and indirect productivity costs of a disease burden, and cost-effectiveness associated with the use of pharmaceuticals.

His extensive research is reflected in over 100 peer-reviewed publications in prominent clinical and health economics journals, such as *Neurology*, *Journal of Allergy and Clinical Immunology*, *Journal of the American Society of Nephrology*, *Cancer*, *Hypertension*, *American Journal of Managed Care*, *Journal of Managed Care Pharmacy*, *Value in Health*, and *PharmacoEconomics*. His scientific research has also resulted in numerous presentations at health care conferences as well as presentations to the FDA and CMS, and has included several high-profile studies publicized in the media, including a recent article on the economic burden of vasomotor symptoms in post-menopausal women cited in *The Wall Street Journal* blog *Pharmalot*.

Mr. Lefebvre has also served as a peer reviewer for several journals, including *CHEST*, *Annals of Oncology*, *Clinical Journal of the American Society of Nephrology*, *Allergy & Asthma Proceedings*, *Journal of Managed Care Pharmacy*, *American Journal of Managed Care*, *Value in Health*, *PharmacoEconomics*. He is also a member of the International Society of Pharmacoepidemiology and the International Society of Pharmacoeconomics and Outcomes Research. Prior to joining Analysis Group, Mr. Lefebvre was an economist with the Québec Ministry of Finance.

**EDUCATION**

|      |                                                      |
|------|------------------------------------------------------|
| 2001 | M.A., economics, Laval University, Québec, Canada    |
| 1998 | B.Sc., mathematics, Laval University, Québec, Canada |

## PROFESSIONAL EXPERIENCE

- 2001–Present    Groupe d'analyse/Analysis Group, Montréal, Canada  
                    *Managing Principal (2016–Present)*  
                    *Vice President (2008–2016)*  
                    *Senior Economist and Manager (2004–2007)*  
                    *Economist and Associate (2001–2003)*
- 2000–2001      Ministry of Finance in Québec, Québec, Canada  
                    *Economist*
- 1998–2000      Department of Economics, Laval University, Québec, Canada  
                    *Research and Teaching Assistant*

## PROFESSIONAL AFFILIATIONS

Journal Peer Reviewer, *CHEST*, *Annals of Oncology*, *Acta Oncologica*, *Clinical Journal of the American Society of Nephrology*, *Nephrology Dialysis Transplantation*, *Allergy & Asthma Proceedings*, *Journal of Managed Care Pharmacy*, *American Journal of Managed Care*, *PLOS ONE*, *Value in Health*, *Pharmacoeconomics*, *Expert Review of Pharmacoeconomics & Outcomes Research*, *Current Medical Research Opinion*, and *Journal of Medical Economics*

Member, International Society of Pharmacoeconomics and Outcomes Research

## JOURNAL PUBLICATIONS

- Desai U, Kharat A, Hess CN, Milentijevic D, Laliberte F, Zuckerman P, Benson J, Lefebvre P, Hiatt WR, Bonaca MP. Healthcare resource utilization and costs of major atherothrombotic vascular events among patients with peripheral artery disease after revascularization. *Journal of Medical Economics* 2021 03; 24(1): 402-409.
- Freedland SJ, Li S, Pilon D, Bhak RH, Narkhede S, Lefebvre P, Young-Xu Y. Medication patterns of abiraterone acetate plus prednisone or enzalutamide and PSA progression in veterans with metastatic castration-resistant prostate cancer. *Current Medical Research and Opinion* 2021 02: 1-14. doi: 10.1080/03007995.2021.1888704.
- Cheng WY, Satija A, Cheung HC, Hill K, Wert T, Laliberté F, Lefebvre P. Persistence to hypomethylating agents and clinical and economic outcomes among patients with myelodysplastic syndromes. *Hematology* 2021 02; 26(1): 261-270. doi: 10.1080/16078454.2021.1889161.
- Freedland SJ, Pilon D, Bhak RH, Lefebvre P, Li S, Young-Xu Y. Predictors of survival, healthcare resource utilization, and healthcare costs in veterans with non-metastatic castration-resistant prostate cancer. *Urologic Oncology: Seminars and Original Investigations* 2020 12; 38(12): 930.e913-930.e921. doi: <https://doi.org/10.1016/j.urolonc.2020.07.002>.
- Chow W, Donga P, Côté-Sergent A, Rossi C, Lefebvre P, Lafeuille M-H, Hardy H, Emond B. Treatment Patterns and Predictors of Adherence in HIV Patients Receiving Single-or Multiple-Tablet Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide. *Patient Preference and Adherence* 2020 12; 14: 2315-2326.

- Zhdanava M, Kuvadia H, Joshi K, Daly E, Pilon D, Rossi C, Morrison L, Lefebvre P, Nelson C. Economic burden of treatment-resistant depression in privately insured US patients with co-occurring anxiety disorder and/or substance use disorder. *Current Medical Research and Opinion* 2020 10: 1. e-pub ahead of print 2020/10/31. doi: 10.1080/03007995.2020.1844645.
- Huang Q, Emond B, Lafeuille M, Gupta D, Lefebvre P, Sundaram M, Mato A. Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia. *Current Medical Research and Opinion* 2020 10: 1-10. doi: 10.1080/03007995.2020.1835851.
- Manceur AM, Ding Z, Muser E, Obando C, Voelker J, Pilon D, Kinkead F, Lafeuille MH, Lefebvre P. Burden of Crohn's disease in the United States: long-term healthcare and work-loss related costs. *Journal of Medical Economics* 2020 Jul 14;1-10. doi: 10.1080/13696998.2020.1789649.
- Zhdanava M, Kuvadia H, Joshi K, Daly E, Pilon D, Rossi C, Morrison L, Lefebvre P, Nelson C. Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions. *Journal of Managed Care & Specialty Pharmacy* 2020 06; 0(0): 1-12. doi: 10.18553/jmcp.2020.20017.
- Hudesman DP, Chakravarty SD, Emond B, Ellis LA, Lefebvre P, Sadik K, Scher JU. Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study. *BMC Rheumatology* 2020 04; 4(1): 16. doi: 10.1186/s41927-020-0115-2.
- Chow W, Donga P, Côté-Sergent A, Rossi C, Lefebvre P, Lafeuille M-H, Emond B, Hardy H. An assessment of weight change associated with the initiation of a protease or integrase strand transfer inhibitor in patients with Human Immunodeficiency Virus. *Current Medical Research and Opinion* 2020 Mar: 1-1. doi: 10.1080/03007995.2020.1775074.
- El Khoury AC, Pilon D, Morrison L, Shak N, Llaneza A, Kim E, Lefebvre P. Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with Schizophrenia. *Journal of Managed Care & Specialty Pharmacy* 2020 Feb; 26(2): 176-185. e-pub ahead of print 2020/02/06; doi: 10.18553/jmcp.2020.26.2.176.
- Patel C, Emond B, Lafeuille MH, Cote-Sergent A, Lefebvre P, Tandon N, El Khoury AC. Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate. *Drugs – Real World Outcomes*. 2020 03; 7(1):19-29. e-pub ahead of print 2019/12/02; doi: 10.1007/s40801-019-00172-9.
- Benson C, Emond B, Lefebvre P, Lafeuille M-H, Côté-Sergent A, Tandon N, Chow W, Dunn K. Rapid Initiation of Antiretroviral Therapy Following Diagnosis of Human Immunodeficiency Virus Among Patients with Commercial Insurance Coverage. *Journal of Managed Care & Specialty Pharmacy*. 2020 02; 26(2):129-141. doi: 10.18553/jmcp.2019.19175.
- Benson C, Emond B, Romdhani H, Lefebvre P, Côté-Sergent A, Shohoudi A, Tandon N, Chow W, Dunn K. Long-Term Benefits of Rapid Antiretroviral Therapy Initiation in Reducing Medical and Overall Health Care Costs Among Medicaid-Covered Patients with Human Immunodeficiency Virus. *Journal of Managed Care & Specialty Pharmacy*. 2020 02; 26(2):117-128. doi: 10.18553/jmcp.2019.19174.

- Pilon D, Szukis H, Singer D, Morrison L, Sheehan JJ, Lefebvre P. Use of home health and other healthcare delivery pathways among privately-insured patients with and without treatment-resistant depression. *Current Medical Research and Opinion*. 2020 Feb 8;1-10. doi: 10.1080/03007995.2020.1722081.
- Khorana AA, McCrae KR, Milentijevic D, Laliberté F, Lejeune D, Crivera C, Lefebvre P. Healthcare resource utilization and costs associated with venous thromboembolism recurrence in patients with cancer. *Journal of Medical Economics*. 2020 Jan 11;1-7. doi: 10.1080/13696998.2019.1703190.
- Manceur AM, Durkin M, Kharat A, Bookhart B, Lafeuille MH, Pilon D, Fakih I, Lefebvre P. Costs associated with renal and cardiovascular events among patients with type 2 diabetes mellitus and nephropathy: a cost model based on the CREDENCE clinical trial. *Current Medical Research and Opinion* 2020 Jan 9: 1-8. e-pub ahead of print 2020/01/10; doi: 10.1080/03007995.2019.1708285.
- Chowdhury S, Oudard S, Uemura H, Joniau S, Pilon D, Lefebvre P, McQuarrie K, Liu J, Dearden L, Sermon J, Van Sanden S, Diels J, Hadaschik BA. Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer. *Advances in Therapy*. 2020 01; 37(1):512-526. e-pub ahead of print 2019/12/10; doi: 10.1007/s12325-019-01157-4.
- Rodgers RF, DuBois R, Thiebaut S, Jaussent I, Maimoun L, Seneque M, Lefebvre P, Renard E, Courtet P, Guillaume S. Structural differences in eating disorder psychopathology after history of childhood abuse: Insights from a Bayesian network analysis. *Journal of Abnormal Psychology*. 2019 11;128(8):795-805. doi: 10.1037/abn0000470. Epub 2019 Oct 10.
- Wysham CH, Gauthier-Loiselle M, Bailey RA, Manceur AM, Lefebvre P, Greenberg M, Duh MS, Young JB. Development of risk models for major adverse chronic renal outcomes among patients with type 2 diabetes mellitus using insurance claims: a retrospective observational study. *Current Medical Research and Opinion*. 2019 10: 1. e-pub ahead of print 2019/10/19; doi: 10.1080/03007995.2019.1682981.
- Pilon D, Joshi K, Sheehan JJ, Zichlin ML, Zuckerman P, Lefebvre P, Greenberg PE. Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis. *PLOS One*. 2019 10; 14(10): e0223255. e-pub ahead of print 2019/10/11; doi: 10.1371/journal.pone.0223255.
- Emond B, Sundaram M, Romdhani H, Lefebvre P, Wang S, Mato A. Comparison of Time to Next Treatment, Health Care Resource Utilization, and Costs in Patients with Chronic Lymphocytic Leukemia Initiated on Front-line Ibrutinib or Chemoimmunotherapy. *Clinical Lymphoma, Myeloma & Leukemia*. 2019 08. e-pub ahead of print 2019/11/05; doi: 10.1016/j.clml.2019.08.004.
- Kavati A, Zhdanava M, Ortiz B, LeCocq J, Schiffman B, Pilon D, Cheung HC, Lefebvre P, Stone BS. Long-term omalizumab outcomes in chronic idiopathic urticaria: A real-world study. *Allergy Asthma Proc*. E-pub ahead of print 2019 Jul 25; doi: 10.2500/aap.2019.40.4236.
- Pergola PE, Pecoits-Filho R, Winkelmayer WC, Spinowitz B, Rochette S, Thompson-Leduc P, Lefebvre P, Shafai G, Bozas A, Sanon M, Krasa HB. Economic Burden and Health-Related Quality of Life Associated with Current Treatments for Anaemia in Patients with CKD not on Dialysis: A Systematic Review. *Pharmacoecon Open*. E-pub ahead of print 2019 Apr 9; doi: 10.1007/s41669-019-0132-5.

- Khorana AA, McCrae KR, Milentijevic D, Fortier J, Nelson WW, Laliberté F, Crivera C, Lefebvre P, Schein J. Duration of anticoagulant therapy and VTE recurrence in patients with cancer. *Support Care Cancer*. 2019 Oct;27(10):3833-3840. E-pub 2019 Feb 8; doi: 10.1007/s00520-019-4661-3.
- Pilon D, El Khoury AC, Manceur AM, Zhdanava M, Benson C, Lefebvre P, Doshi JA. Are Medicaid Coverage Gaps Associated with Higher Health Care Resource Utilization and Costs in Patients with Schizophrenia? *Population Health Management*. 2019 10. e-pub ahead of print 2019/10/09; doi: 10.1089/pop.2019.0147.
- Kavati A, Zhdanava M, Ortiz B, Lecocq J, Schiffman B, Pilon D, Ho H, Lefebvre P, Stone B. Retrospective Study on the Association of Biomarkers With Real-world Outcomes of Omalizumab-treated Patients With Allergic Asthma. *Clinical Therapeutics*. 2019 10; 41(10):1956-1971. doi: 10.1016/j.clinthera.2019.07.021. Epub 2019 Sep 25.
- Shah BR, DerSarkissian M, Tsintzos SI, Xiao Y, May D, Lu X, Kinrich D, Davis E, Lefebvre P, Duh MS, Dasta JF. Adherence to heart failure management medications following cardiac resynchronization therapy. *Current Medical Research and Opinion*. 2019 09; 1. e-pub ahead of print 2019/09/20; doi: 10.1080/03007995.2019.1670474.
- Greenberg B, Peterson ED, Berger JS, Laliberté F, Zhao Q, Germain G, Lejeune D, Wu JW, Lefebvre P, Fonarow GC. Ejection fraction, B-type natriuretic peptide and risk of stroke and acute myocardial infarction among patients with heart failure. *Clin Cardiol*. 2019 Feb;42(2):277-284. E-pub 2019 Jan 7; doi: 10.1002/clc.23140.
- Wysham CH, Lefebvre P, Pilon D, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Duh MS, Ingham M. An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records. *J Diabetes Complications*. 2019 Feb;33(2):140-147. E-pub 2018 Oct 31; doi: 10.1016/j.jdiacomp.2018.10.016.
- Pilon D, Sheehan JJ, Szukis H, Morrison L, Zhdanava M, Lefebvre P, Joshi K. Is clinician impression of depression symptom severity associated with incremental economic burden in privately insured US patients with treatment resistant depression? *Journal of Affective Disorders* 2019 08; 255: 50-59. doi: <http://dx.doi.org/10.1016/j.jad.2019.04.100>.
- Emond B, Joshi K, Khoury ACE, Lafeuille MH, Pilon D, Tandon N, Romdhani H, Lefebvre P. Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate. *PharmacoEconomics - Open* 2019 06; 3(2): 177-188. doi: <http://dx.doi.org/10.1007/s41669-018-0089-9>.
- Pilon D, Szukis H, Joshi K, Singer D, Sheehan JJ, Wu JW, Lefebvre P, Greenberg P. US Integrated Delivery Networks Perspective on Economic Burden of Patients with Treatment-Resistant Depression: A Retrospective Matched-Cohort Study. *PharmacoEconomics Open* 2019 06. E-pub ahead of print 2019/06/30; doi: 10.1007/s41669-019-0154-z.
- Pilon D, Ellis LA, Xiao Y, Behl AS, Lefebvre P. Consideration of Potential Drug-Drug Interactions in Selection of FDA-Approved Drugs Indicated for Prostate Cancer. *American Journal of Therapeutics* 2019 05; 26(3): e422-e424. doi: <http://dx.doi.org/10.1097/MJT.0000000000000693>.
- Rozjabek HM, Coleman CI, Ashton V, Laliberte F, Oyefesobi P, Lejeune D, Germain G, Schein JR, Yuan Z, Lefebvre P, Peterson ED. Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants. *Journal of Medical*

*Economics*. 2019 05: 1-9. E-pub ahead of print 2019/04/04; doi: <http://dx.doi.org/10.1080/13696998.2019.1603156>.

- Streiff M, Milentijevic D, McCrae KR, Laliberte F, Lejeune D, Lefebvre P, Schein J, Khorana AA. Healthcare resource utilization and costs associated with venous thromboembolism in cancer patients treated with anticoagulants. *Journal of Medical Economics* 2019 05: 1. doi: <http://dx.doi.org/10.1080/13696998.2019.1620752>.
- Emond B, Ellis LA, Chakravarty SD, Ladouceur M, Lefebvre P. Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors. *Current Medical Research and Opinion* 2019 05: 1-9. E-pub ahead of print 2019/05/21; doi: 10.1080/03007995.2019.1620713.
- Pilon D, Sheehan JJ, Szukis H, Singer D, Jacques P, Lejeune D, Lefebvre P, Greenberg PE. Medicaid spending burden among beneficiaries with treatment-resistant depression. *Journal of Comparative Effectiveness Research* 2019 04; 8(6): 381-392. E-pub ahead of print 2019/02/09; doi: 10.2217/cer-2018-0140.
- McHorney CA, Peterson ED, Ashton V, Laliberte F, Crivera C, Germain G, Sheikh N, Schein J, Lefebvre P. Modeling the impact of real-world adherence to once-daily (QD) versus twice-daily (BID) non-vitamin K antagonist oral anticoagulants on stroke and major bleeding events among non-valvular atrial fibrillation patients. *Current Medical Research and Opinion* 2019 04; 35(4): 653-660. doi: <http://dx.doi.org/10.1080/03007995.2018.1530205>.
- Brunton S, Rozjabek HM, Pilon D, Lafeuille MH, Kamstra R, Wynant W, Bookhart BK, Lefebvre P. Real-world impact of glycated hemoglobin reduction on treatment intensification and glycated hemoglobin goal attainment in type 2 diabetes mellitus patients initiated on a sodium glucose co-transporter 2 (SGLT2) inhibitor (SGLT2i). *Current Medical Research and Opinion* 2019 04: 1-8. E-pub ahead of print 2019/04/10; doi: 10.1080/03007995.2019.1605160.
- Kamstra R, Durkin M, Cai J, Bookhart B, Lafeuille MH, Pilon D, Tiggelaar S, Manceur AM, Lefebvre P. Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials. *Journal of Medical Economics* 2019 03; 22(3): 280-287. E-pub ahead of print 2018/12/24; doi: 10.1080/13696998.2018.1562817.
- Emond B, El Khoury AC, Patel C, Pilon D, Morrison L, Zhdanava M, Lefebvre P, Tandon N, Joshi K. Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans. *Current Medical Research and Opinion*. 2019 03; 35(3):407-416. doi: <http://dx.doi.org/10.1080/03007995.2018.1560220>.
- Pilon D, Teeple A, Zhdanava M, Ladouceur M, Ching Cheung H, Muser E, Lefebvre P. The economic burden of psoriasis with high comorbidity among privately insured patients in the United States. *Journal of Medical Economics*. 2019 02; 22(2): 196-203. E-pub ahead of print 2018/12/14; doi: 10.1080/13696998.2018.1557201.
- Spinowitz B, Pecoits-Filho R, Winkelmayr WC, Pergola PE, Rochette S, Thompson-Leduc P, Lefebvre P, Shafai G, Bozas A, Sanon M, Krasa HB. Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review. *Journal of Medical Economics* 2019 02: 1-12. E-pub ahead of print 2019/03/01; doi: 10.1080/13696998.2019.1588738.

- Skotko BG, Samuelson D, Kageleiry A, Lefebvre P, Hellstern M, Campbell J. Comment on “The price of abandoning diagnostics testing for cell-free fetal DNA screening.” *Prenatal Diagnosis* 2019 01; 39(2): 130. doi: <http://dx.doi.org/10.1002/pd.5331>.
- Pilon D, Amos TB, Kamstra R, Manceur AM, El Khoury AC, Lefebvre P. Short-term rehospitalizations in young adults with schizophrenia treated with once-monthly paliperidone palmitate or oral atypical antipsychotics: a retrospective analysis. *Current Medical Research and Opinion*. 2018 09: 1-9. E-pub ahead of print 2018/08/15; doi: 10.1080/03007995.2018.1512477.
- Khorana AA, McCrae K, Milentijevic D, McCormick N, Laliberte F, Crivera C, Lefebvre P, Lejeune D, Rozjabek H, Schein J, Streiff MB. The risk of recurrent VTE and major bleeding in a commercially-insured population of cancer patients treated with anticoagulation. *American Journal of Hematology*. 2018 11. E-pub ahead of print 2018/11/27; doi: 10.1002/ajh.25361.
- Laliberte F, Coleman CI, Bookhart B, Schein J, Martin S, Wynant W, Xiao Y, Lefebvre P, Kaatz S. CMS hospital readmission reduction program and anticoagulants received following a total hip and knee arthroplasty discharge. *Current Medical Research and Opinion*. 2018 06; 34(11): 1967-1974. E-pub ahead of print 2018/05/12; doi: 10.1080/03007995.2018.1475347.
- Williams P, Kavati A, Pilon D, Xiao Y, Zhdanava M, Balp MM, Lefebvre P, Ortiz B, Hernandez-Trujillo V. Health care burden and treatment patterns in commercially insured children with chronic idiopathic/spontaneous urticaria: A real-world study in the United States. *Allergy and Asthma Proceedings*. 2018 05; 39(3): 201-211. E-pub ahead of print 2018/03/09; doi: 10.2500/aap.2018.39.4129.
- Eghrari-Sabet J, Sher E, Kavati A, Pilon D, Zhdanava M, Balp MM, Lefebvre P, Ortiz B, Bernstein JA. Real-world use of omalizumab in patients with chronic idiopathic/spontaneous urticaria in the United States. *Allergy and Asthma Proceedings*. 2018 05; 39(3): 191-200. E-pub ahead of print 2018/02/21; doi: 10.2500/aap.2018.39.4132.
- Dunn K, Lafeuille M, Jiao X, Romdhani H, Emond B, Woodruff K, Pesa J, Tandon N, Lefebvre P. Adherence to antiretrovirals in medicaid-insured patients living with hiv: Predictors and economic consequences. *Value in Health*. 2018 05; 21 (Supplement 1): S150-S151.
- Streiff MB, Milentijevic D, McCrae K, Yannicelli D, Fortier J, Nelson WW, Laliberte F, Crivera C, Lefebvre P, Schein J, Khorana AA. Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer. *American Journal of Hematology*. 2018 93(5): 664-671. doi: <http://dx.doi.org/10.1002/ajh.25059>.
- Amos TB, Tandon N, Lefebvre P, Pilon D, Kamstra RL, Pivneva I, Greenberg PE. Direct and Indirect Cost Burden and Change of Employment Status in Treatment-Resistant Depression: A Matched-Cohort Study Using a US Commercial Claims Database. *Journal of Clinical Psychiatry*. 2018 02; 79(2). E-pub ahead of print 2018/02/24; doi: 10.4088/JCP.17m11725.
- Pilon D, Kavati A, Ortiz B, Paknis B, Vegesna A, Schiffman B, Zhdanava M, Lefebvre P, Stone B. Asthma control, lung function, symptoms, and corticosteroid sparing after omalizumab initiation in patients with allergic asthma. *Allergy and Asthma Proceedings*. 2018 03; 39(2): 127-135. E-pub ahead of print 2017/12/07; doi: 10.2500/aap.2018.39.4111.

- Williams PV, Kavati A, Pilon D, Xiao Y, Zhdanava M, Balp MM, Lefebvre P, Ortiz B, Hernandez-Trujillo V. Treatment Patterns, Healthcare Resource Utilization, and Spending Among Medicaid-Enrolled Children with Chronic Idiopathic/Spontaneous Urticaria in the United States. *Dermatol Ther. (Heidelb)* 2018 03; 8(1): 69-83. E-pub ahead of print 2018/02/13; doi: 10.1007/s13555-018-0225-6.
- Wang S, Lafeuille MH, Lefebvre P, Romdhani H, Emond B, Senbetta M. Economic burden of treatment failure in chronic lymphocytic leukemia patients. *Current Medical Research and Opinion*. 2018 06; 34(6): 1135-1142. E-pub ahead of print 2018/04/14; doi: 10.1080/03007995.2018.1464904.
- Wysham CH, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Lefebvre P. Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting. *Current Medical Research and Opinion*. 2018 05; 34(6): 1125-1133. E-pub ahead of print 2018/03/21; doi: 10.1080/03007995.2018.1454417.
- Tanton D, Duh MS, Lafeuille MH, Lefebvre P, Pilon D, Zhdanava M, Emond B, Inman D, Bailey RA. Real-world evaluation of HbA1c, blood pressure, and weight loss among patients with type 2 diabetes mellitus treated with canagliflozin: an analysis of electronic medical records from a network of hospitals in Florida. *Current Medical Research and Opinion*. 2018 05; 34(6): 1099-1115. E-pub ahead of print 2018/02/23; doi: 10.1080/03007995.2018.1444591.
- Yan S, DerSarkissian M, Bhak RH, Lefebvre P, Duh MS, Krishnarajah G. Relationship between patient copayments in Medicare Part D and vaccination claim status for herpes zoster and tetanus-diphtheria-acellular pertussis. *Current Medical Research and Opinion*. 2018 07; 34(7): 1261-1269. E-pub ahead of print 2017/12/13; doi: 10.1080/03007995.2017.1416347.
- Berger JS, Seheult R, Laliberte F, Crivera C, Lejeune D, Xiao Y, Schein J, Lefebvre P, Kaatz S. Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism. *Research and Practice in Thrombosis and Haemostasis*. 2018 01; 2(1): 58-68. doi: <http://dx.doi.org/10.1002/rth2.12050>.
- Pilon D, Alcusky M, Xiao Y, Thompson-Leduc P, Lafeuille MH, Lefebvre P, Benson C. Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics. *Journal of Medical Economics*. 2018 02; 21(2): 135-143. E-pub ahead of print 2017/09/13; doi: 10.1080/13696998.2017.1379413.
- Wells PS, Prins MH, Beyer-Westendorf J, Lensing AWA, Haskell L, Levitan B, Laliberte F, Ashton V, Xiao Y, Lejeune D, Crivera C, Lefebvre P, Zhao Q, Yuan Z, Schein J, Prandoni P. Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population. *Chest*. 2018 12; 154(6): 1371-1378. doi: <http://dx.doi.org/10.1016/j.chest.2018.08.1059>.
- Young JB, Gauthier-Loiselle M, Bailey RA, Manceur AM, Lefebvre P, Greenberg M, Lafeuille MH, Duh MS, Bookhart B, Wysham CH. Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data. *Cardiovascular Diabetology*. 2018 08; 17(1): 118. E-pub ahead of print 2018/08/26; doi: 10.1186/s12933-018-0759-z.



- DerSarkissian M, Lefebvre P, Joshi K, Brown B, Lafeuille MH, Bhak RH, Hellstern M, Bobbili P, Shiner B, El Khoury AC, Young-Xu Y. Health Care Resource Utilization and Costs Associated with Transitioning to 3-Month Paliperidone Palmitate Among US Veterans. *Clinical Therapeutics*. 2018 08. E-pub ahead of print 2018/08/27; doi: 10.1016/j.clinthera.2018.07.011.
- Kamstra R, Pilon D, Lefebvre P, Emond B, Joshi K. Treatment patterns and Medicaid spending in comorbid schizophrenia populations: once-monthly paliperidone palmitate versus oral atypical antipsychotics. *Current Medical Research and Opinion*. 2018 02; 34(8): 1377-1388. E-pub ahead of print 2018/02/18; doi: 10.1080/03007995.2018.1442822.
- Wells PS, Lensing AWA, Haskell L, Levitan B, Laliberte F, Durkin M, Ashton V, Xiao Y, Crivera C, Lejeune D, Schein J, Lefebvre P. Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results. *Journal of Medical Economics*. 2018 06; 21(6): 587-594.
- Wysham CH, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Lefebvre P. HbA1c control and cost-effectiveness in patients with type 2 diabetes mellitus initiated on canagliflozin or a glucagon-like peptide 1 receptor agonist in a real-world setting. *Endocrine Practice*. 2018 03; 24(3): 273-287. doi: <http://dx.doi.org/10.4158/EP-2017-0066>.
- Dunn K, Lafeuille MH, Jiao X, Romdhani H, Emond B, Woodruff K, Pesa J, Tandon N, Lefebvre P. Risk Factors, Health Care Resource Utilization, and Costs Associated with Nonadherence to Antiretrovirals in Medicaid-Insured Patients with HIV. *Journal of Managed Care & Specialty Pharmacy*. 2018 10; 24(10): 1040-1051. doi: <http://dx.doi.org/10.18553/jmcp.2018.17507>.
- Weir MR, Haskell L, Berger JS, Ashton V, Laliberte F, Crivera C, Brown K, Lefebvre P, Schein J. Evaluation of clinical outcomes among nonvalvular atrial fibrillation patients treated with rivaroxaban or warfarin, stratified by renal function. *Clinical Nephrology*. 2018 05; 89(5): 314-329. doi: <http://dx.doi.org/10.5414/CN109281>.
- Kaatz S, Coleman CI, Bookhart B, Laliberte F, Nelson WW, Brown K, Martin S, Schein J, Lefebvre P. Implications of stroke and bleeding risk scores and comorbidities on episode-based bundled payments for patients with nonvalvular atrial fibrillation. *Current Medical Research and Opinion*. 2018 34(2): 275-284. doi: <http://dx.doi.org/10.1080/03007995.2017.1409200>.
- McHorney CA, Crivera C, Laliberte F, Germain G, Wynant W, Lefebvre P. Adherence to rivaroxaban versus apixaban among patients with non-valvular atrial fibrillation: Analysis of overall population and subgroups of prior oral anticoagulant users. *PloS One*. 2018 04; 13(4): e0194099. E-pub ahead of print 2018/04/06; doi: 10.1371/journal.pone.0194099.
- Streiff MB, Milentijevic D, McCrae K, Yannicelli D, Lejeune D, Nelson WW, Laliberte F, Crivera C, Lefebvre P, Schein J, Khorana AA. An answer to “anticoagulant treatment of cancer-associated venous thromboembolism: Interpreting real-world data with caution.” *American Journal of Hematology*. 2018 01. doi: <http://dx.doi.org/10.1002/ajh.25165>.
- Kavati A, Pilon D, Ortiz B, Paknis B, Vegesna A, Schiffman B, Zhdanava M, Lefebvre P, Stone B. Description of Baseline Characteristics of Pediatric Allergic Asthma Patients Including those Initiated on Omalizumab. *Allergy and Rhinology*. 2018 04; 9(no pagination). doi: <http://dx.doi.org/10.1177/2152656718763387>.

- El Khoury AC, Pilon D, Morrison L, Shak N, Vermette-Laforme M, Amos TB, Kim E, Lefebvre P. The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia. *Current Medical Research and Opinion*. 2018 12. doi: <http://dx.doi.org/10.1080/03007995.2018.1558195>.
- Berger JS, Peterson E, Laliberte F, Germain G, Lejeune D, Schein J, Lefebvre P, Zhao Q, Weir MR. Risk of Ischemic Stroke in Patients Newly Diagnosed With Heart Failure: Focus on Patients Without Atrial Fibrillation. *Journal of Cardiac Failure*. 2018 05.
- Krishnarajah G, Kageleiry A, Korves C, Lefebvre P, Duh MS. Public health impact of Rotarix vaccination among commercially insured children in the United States. *Vaccine*. 2017 09; 35(37): 5065-5072. E-pub ahead of print 2017/08/06; doi: 10.1016/j.vaccine.2017.06.034.
- Joshi K, Lafeuille MH, Brown B, Wynant W, Emond B, Lefebvre P, Tandon N. Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting. *Current Medical Research and Opinion*. 2017 08; 33(10): 1763-1772. E-pub ahead of print 2017/07/26; doi: 10.1080/03007995.2017.1359516.
- Weir MR, Berger JS, Ashton V, Laliberte F, Brown K, Lefebvre P, Schein J. Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence. *Current Medical Research and Opinion*. 2017 10; 33(10): 1891-1900. E-pub ahead of print 2017/06/08; doi: 10.1080/03007995.2017.1339674.
- Pilon D, Tandon N, Lafeuille MH, Kamstra R, Emond B, Lefebvre P, Joshi K. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics. *Clinical Therapeutics*. 2017 09; 39(10): 1972-1985 e1972. E-pub ahead of print 2017/09/19; doi: 10.1016/j.clinthera.2017.08.008.
- Kageleiry A, Samuelson D, Duh MS, Lefebvre P, Campbell J, Skotko BG. Out-of-pocket medical costs and third-party healthcare costs for children with Down syndrome. *American Journal of Medical Genetics. Part A* 2017 12; 173(3): 627-637. E-pub ahead of print 2016/12/15; doi: 10.1002/ajmg.a.38050.
- Wysham CH, Lefebvre P, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Chow W, Pfeifer M, Duh MS. Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors. *BMC Endocrine Disorders*. 2017 06; 17(1): 32. E-pub ahead of print 2017/06/10; doi: 10.1186/s12902-017-0180-8.
- Coleman C, Yuan Z, Schein J, Crivera C, Ashton V, Laliberte F, Lefebvre P, Peterson ED. Importance of balancing follow-up time and impact of oral-anticoagulant users' selection when evaluating medication adherence in atrial fibrillation patients treated with rivaroxaban and apixaban. *Current Medical Research and Opinion*. 2017 06; 33(6): 1033-1043. doi: 10.1080/03007995.2017.1297932.
- Khorana AA, McCrae KR, Milentijevic D, Fortier J, Nelson WW, Laliberte F, Crivera C, Lefebvre P, Yannicelli D, Schein J. Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis. *Research and Practice in Thrombosis and Haemostasis*. 2017 07; 1(1): 14-22. doi: <http://dx.doi.org/10.1002/rth2.12002>.

- Lefebvre P, Muser E, Joshi K, DerSarkissian M, Bhak RH, Duh MS, Shiner B, Young-Xu Y. Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans With Schizophrenia and Comorbid Substance Abuse. *Clinical Therapeutics*. 2017 07; 39(7): 1380-1395 e1384. E-pub ahead of print 2017/06/24; doi: 10.1016/j.clinthera.2017.05.356.
- Lefebvre P, Duh MS, Lafeuille MH, Gozalo L, Desai U, Robitaille MN, Albers F, Yancey S, Ortega H, Forshag M, Lin X, Dalal AA. Burden of systemic glucocorticoid-related complications in severe asthma. *Current Medical Research and Opinion*. 2017 01; 33(1): 57-65. E-pub ahead of print 2016/09/15; doi: 10.1080/03007995.2016.1233101.
- Nelson WW, Laliberte F, Patel AA, Germain G, Pilon D, McCormick N, Lefebvre P. Stroke risk reduction outweighed bleeding risk increase from vitamin K antagonist treatment among nonvalvular atrial fibrillation patients with high stroke risk and low bleeding risk. *Current Medical Research and Opinion*. 2017 04; 33(4): 631-638. doi: 10.1080/03007995.2016.1275936.
- Pilon D, Amos TB, Germain G, Lafeuille MH, Lefebvre P, Benson CJ. Treatment persistence and hospitalization rates among patients with schizophrenia: a quasi-experiment to evaluate a patient information program. *Current Medical Research and Opinion*. 2017 04; 33(4): 713-721. doi: 10.1080/03007995.2016.1277989.
- Pilon D, Joshi K, Tandon N, Lafeuille MH, Kamstra RL, Emond B, Lefebvre P. Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic. *Patient Preference and Adherence*. 2017 03; 11: 619-629. doi: <http://dx.doi.org/10.2147/PPA.S127623>.
- Mapel D, Laliberte F, Roberts MH, Sama SR, Sundaresan D, Pilon D, Lefebvre P, Duh MS, Patel J. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy. *International Journal of Chronic Obstructive Pulmonary Disease*. 2017 06; 12: 1825-1836. E-pub ahead of print 2017/07/08; doi: 10.2147/COPD.S129007.
- McHorney CA, Ashton V, Laliberte F, Germain G, Wynant W, Crivera C, Schein JR, Lefebvre P, Peterson ED. Adherence to rivaroxaban compared with other oral anticoagulant agents among patients with nonvalvular atrial fibrillation. *Journal of Managed Care and Specialty Pharmacy*. 2017 09; 23(9): 980-988. doi: <http://dx.doi.org/10.18553/jmcp.2017.23.9.980>.
- Khorana AA, Berger JS, Wells PS, Seheult R, Ashton V, Laliberte F, Crivera C, Lejeune D, Schein J, Wildgoose P, Lefebvre P, Kaatz S. Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE. *Clinical Therapeutics*. 2017 07; 39(7): 1396-1408. doi: <http://dx.doi.org/10.1016/j.clinthera.2017.05.357>.
- Pilon D, Ellis LA, Behl AS, Gozalo L, Emond B, Lefebvre P, Calabrese R, Prime H, Gaylis F. Assessment of Evidence-Based Standards in the Treatment of Advanced Prostate Cancer in a Community Practice. *Urology Practice*. 2017 04; 4(3): 218-224. doi: <http://dx.doi.org/10.1016/j.urpr.2016.06.004>.
- Pilon D, Behl AS, Ellis LA, Robitaille MN, Lefebvre P, Dawson NA. Assessment of real-world central nervous system events in patients with advanced prostate cancer using abiraterone acetate, bicalutamide, enzalutamide, or chemotherapy. *American Health and Drug Benefits*. 2017 05; 10(3): 143-152.

- Pilon D, Behl AS, Ellis LA, Emond B, Lefebvre P, Dawson NA. Duration of treatment in prostate cancer patients treated with abiraterone acetate or enzalutamide. *Journal of Managed Care and Specialty Pharmacy*. 2017 02; 23(2): 225-235. doi: <http://dx.doi.org/10.18553/jmcp.2016.16233>.
- DerSarkissian M, Xiao Y, Duh MS, Lefebvre P, Swensen AR, Bell CF. Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States. *Journal of Managed Care and Specialty Pharmacy*. 2016 10; 22(10): 1204-1214. doi: 10.18553/jmcp.2016.22.10.1204.
- Lafeuille MH, Frois C, Cloutier M, Duh MS, Lefebvre P, Pesa J, Clancy Z, Fastenau J, Durkin M. Factors Associated with Adherence to the HEDIS Quality Measure in Medicaid Patients with Schizophrenia. *American Health & Drug Benefits*. 2016 10; 9(7): 399-410. E-pub ahead of print 2016/12/21.
- Young-Xu Y, Duh MS, Muser E, DerSarkissian M, Faust E, Kageleiry A, Bhak RH, Fu DJ, Lefebvre P, Shiner B. Impact of Paliperidone Palmitate versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans with Schizophrenia. *Journal of Clinical Psychiatry*. 2016 10; 77(10): e1332-e1341. E-pub ahead of print 2016/08/31; doi: 10.4088/JCP.16m10745.
- McHorney CA, Peterson ED, Laliberte F, Germain G, Nelson WW, Crivera C, Schein J, Lefebvre P. Comparison of Adherence to Rivaroxaban versus Apixaban Among Patients with Atrial Fibrillation. *Clinical Therapeutics*. 2016 11; 38(11): 2477-2488. doi: 10.1016/j.clinthera.2016.09.014.
- Ma E, Bonthapally V, Chawla A, Lefebvre P, Swords R, Lafeuille MH, Fortier J, Emond B, Duh MS, Dezube BJ. An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed with Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records from US Community Oncology Practices. *Clinical Lymphoma, Myeloma & Leukemia*. 2016 10; 16(11): 625-636 e623. E-pub ahead of print 2016/10/01; doi: 10.1016/j.clml.2016.08.006.
- Lefebvre P, Pilon D, Robitaille MN, Lafeuille MH, Chow W, Pfeifer M, Duh MS. Real-world glycemic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozin-an electronic health-record-based study. *Current Medical Research and Opinion*. 2016 06; 32(6): 1151-1159. E-pub ahead of print 2016/04/27; doi: 10.1080/03007995.2016.1183604.
- Dalal AA, Duh MS, Gozalo L, Robitaille MN, Albers F, Yancey S, Ortega H, Forshag M, Lin X, Lefebvre P. Dose-Response Relationship Between Long-Term Systemic Corticosteroid Use and Related Complications in Patients with Severe Asthma. *Journal of Managed Care and Specialty Pharmacy*. 2016 07; 22(7): 833-847. doi: 10.18553/jmcp.2016.22.7.833.
- Law A, Pilon D, Lynen R, Laliberte F, Gozalo L, Lefebvre P, Duh MS. Retrospective analysis of the impact of increasing access to long acting reversible contraceptives in a commercially insured population. *Reproductive Health*. 2016 08; 13(1): 96. E-pub ahead of print 2016/08/24; doi: 10.1186/s12978-016-0211-3.
- Pilon D, Queener MK, Lefebvre P, Ellis LA. Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer. *Journal of Medical Economics*. 2016 Mar 31:1-28.

- Deitelzweig S, Laliberte F, Crivera C, Germain G, Bookhart BK, Olson WH, Schein J, Lefebvre P. Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting. *Clinical Therapeutics*. 2016 08; 38(8): 1803-1816.e1803. doi: <http://dx.doi.org/10.1016/j.clinthera.2016.07.002>.
- Simon JA, Laliberté F, Duh MS, Pilon D, Kahler KH, Nyirady J, Davis PJ, Lefebvre P. Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy. *Menopause*. 2016 Feb 26. [Epub ahead of print]
- Xiao Y, Muser E, Fu DJ, Lafeuille MH, Pilon D, Emond B, Wu A, Duh MS, Lefebvre P. Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics. *Current Medical Research and Opinion*. 2016 Apr;32(4):759-69.
- LaMori J, Tandon N, Laliberté F, Germain G, Pilon D, Lefebvre P, Prabhakar A. Predictors of high healthcare resource utilization and liver disease progression among patients with chronic hepatitis C. *Journal of Medical Economics*. 2016 Apr;19(4):364-73.
- Lefebvre P, Duh MS, Lafeuille MH, Gozalo L, Desai U, Robitaille MN, Albers F, Yancey S, Ortega H, Forshag M, Lin X, Dalal AA. Acute and chronic systemic corticosteroid-related complications in patients with severe asthma. *The Journal of Allergy and Clinical Immunology*. 2015 Dec;136(6):1488-95.
- Olson WH, Ma YW, Crivera C, Schein J, Lefebvre P, Laliberté F, Dea K, Germain G, Lynch SM. Economic outcomes with prasugrel versus clopidogrel in acute coronary syndrome patients: observations from prasugrel users and matched clopidogrel users. *Journal of Medical Economics*. 2015;18(12):1074-84.
- McHorney CA, Crivera C, Laliberté F, Nelson WW, Germain G, Bookhart BK, Martin S, Schein J, Lefebvre P, Deitelzweig S. Adherence to non-vitamin-K-antagonist oral anticoagulant medications based on the Pharmacy Quality Alliance measure. *Current Medical Research and Opinion*. 2015 Dec;31(12):2167-73.
- Merli GJ, Hollander JE, Lefebvre P, Laliberté F, Raut MK, Germain G, Bookhart BK, Pollack CV. Costs of hospital visits among patients with deep vein thrombosis treated with rivaroxaban and LMWH/warfarin. *Journal of Medical Economics*. 2016 Jan;19(1):84-90.
- Vekeman F, Gauthier-Loiselle M, Faust E, Lefebvre P, Lahoz R, Duh MS, Sacco P. Patient and caregiver burden associated with Fragile X syndrome in the United States. *American Journal on Intellectual and Developmental Disabilities*. 2015 Sep;120(5):444-59.
- Kumar SK, Ma E, Engebretson AE, Buadi FK, Lacy MQ, Dispenzieri A, Duh MS, Lafeuille MH, Lefebvre P, Cheng WY, Dea K, Rembert D, Patt D, Niculescu L, Quick M, Rajkumar SV. Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma. *Leukemia*. 2016 04; 30(4): 995-998. E-pub ahead of print 2015/08/15; doi: 10.1038/leu.2015.225.
- Crivera C, Nelson WW, Bookhart BK, Martin S, Germain G, Laliberté F, Schein J, Lefebvre P. Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications. *Current Medical Research and Opinion*. 2015;31(10):1889-95.

- Dasta JF, Pilon D, Mody SH, Lopatto J, Laliberté F, Germain G, Bookhart BK, Lefebvre P, Nutescu EA. Daily costs of hospitalization in non-valvular atrial fibrillation patients treated with anticoagulant therapy. *Journal of Medical Economics*. 26 Aug 2015, 18(12):1041-1049.
- Xiao Y, Muser E, Lafeuille MH, Pesa J, Fastenau J, Duh MS, Lefebvre P. Impact of paliperidone palmitate versus oral atypical antipsychotics on healthcare outcomes in schizophrenia patients. *Journal of Comparative Effectiveness Research* 2015 07; 4(6): 579-592. doi: 10.2217/CER.15.34.
- Ellis LA, Lafeuille MH, Gozalo L, Pilon D, Lefebvre P, McKenzie RS. Treatment sequences and pharmacy costs of two new therapies for metastatic castration-resistant prostate cancer. *Am Health Drug Benefits*. 2015 Jun;8(4):185-95.
- Tandon N, Reddy K, Balart L, Fastenau J, Lefebvre P, Parisé H, Laliberté F, Pilon D, Duh M, Cho M, Prabhakar A. Direct and Indirect Cost Burden of Chronic Hepatitis C. *The American Journal of Pharmacy Benefits* 2015 07; 7(4): e90-e100.
- Kruse G, Wong BJ, Duh MS, Lefebvre P, Lafeuille MH, Fastenau JM. Systematic literature review of the methods used to compare newer second-generation agents for the management of schizophrenia: A focus on health technology assessment. *Pharmacoeconomics*. 2015 Oct;33(10):1049-67.
- Merli GJ, Hollander JE, Lefebvre P, Laliberté F, Raut MK, Olson WH, Pollack CV Jr. Rates of hospitalization among patients with deep vein thrombosis before and after the introduction of rivaroxaban. *Hospital Practice*. 2015;43(2):85-93.
- Laliberté F, Cloutier M, Crivera C, Nelson WW, Olson WH, Schein J, Vanderpoel J, Germain G, Lefebvre P. Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users. *Advances in Therapy*. 2015 Mar;32(3):216-27.
- Laliberté F, Cloutier M, Crivera C, Nelson WW, Olson WH, Schein J, Vanderpoel J, Germain G, Lefebvre P. Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users. *Clinical Therapeutics*. 2015 Mar 1;37(3):554-62.
- Tandon N, Balart LA, Laliberté F, Pilon D, Lefebvre P, Germain G, Prabhakar A. Reply: Essential need for research in hepatitis C. *Journal of Medical Economics*. 2015;18(7):514-5.
- Sarrel P, Portman D, Lefebvre P, Lafeuille MH, Grittner AM, Fortier J, Gravel J, Duh MS, Aupperle PM. Incremental direct and indirect costs of untreated vasomotor symptoms. *Menopause*. 2015 Mar;22(3):260-6.
- Lafeuille MH, Grittner AM, Fortier J, Muser E, Fasteneau J, Duh MS, Lefebvre P. Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics. *I*. 2015 Mar 1;72(5):378-89.
- Dasta JF, Pilon D, Mody SH, Lopatto J, Laliberté F, Germain G, Bookhart BK, Lefebvre P, Nutescu EA. Daily hospitalization costs in patients with deep vein thrombosis or pulmonary embolism treated with anticoagulant therapy. *Thromb Res*. 2015 Feb;135(2):303-10.
- Krishnarajah G, Demissie K, Lefebvre P, Gaur S, Duh MS. Clinical and cost burden of rotavirus infection before and after introduction of rotavirus vaccines among commercially and Medicaid insured children in the United States. *Human Vaccines & Immunotherapeutics*. 2014;10(8):2255-66.

- Laliberté F, Moore Y, Dea K, LaMori JC, Mody SH, Jones JL, Arledge MD, Damaraju CV, Schein JR, Lefebvre P. Gastrointestinal comorbidities associated with atrial fibrillation. *Springerplus*. 2014 Oct 15;3:603.
- Lafeuille MH, Grittner AM, Gravel J, Bailey RA, Martin S, Garber L, Duh MS, Lefebvre P. Economic simulation of canagliflozin and sitagliptin treatment outcomes in patients with type 2 diabetes mellitus with inadequate glycemic control. *Journal of Medical Economics*. 2015 Feb;18(2):113-25.
- Laliberte F, Nutescu EA, Lefebvre P, Rondeau-Leclaire J, Bookhart BK, LaMori JC, Damaraju CV, Schein J, Kaatz S. Risk factors associated with myocardial infarction in venous thromboembolism patients. *Current Medical Research and Opinion*. 2014 01; 30(1): 27-35. doi: 10.1185/03007995.2013.852525.
- Ayyagari R, Vekeman F, Lefebvre P, Ong SH, Faust E, Trahey A, Machnicki G, Duh MS. Pulse pressure and stroke risk: development and validation of a new stroke risk model. *Current Medical Research and Opinion*. 2014 Dec;30(12):2453-60.
- Laliberté F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P. Hospital length of stay of nonvalvular atrial fibrillation patients who were administered Rivaroxaban versus Warfarin with and without pretreatment parenteral anticoagulants therapies. *Hospital Practice*. 2014 Aug;42(3):17-25.
- Tandon N, Balart LA, Laliberté F, Pilon D, Lefebvre P, Germain G, Prabhakar A. Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost. *Journal of Medical Economics*. 2014 Dec;17(12):862-71.
- Olson WH, Ma YW, Laliberte F, Lefebvre P, Crivera C, Schein JR, Fields LE, Dea K, Germain G, Lynch SM. Prasugrel vs. clopidogrel in acute coronary syndrome patients treated with prasugrel. *Journal of Clinical Pharmacy and Therapeutics*. 2014 09; 39(6): 663-672. doi: 10.1111/jcpt.12209.
- Knopf KB, Duh MS, Lafeuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-Mancini A, Ma E, Shi H, Comenzo RL. Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma. *Clin Lymphoma Myeloma Leuk*. 2014 Oct;14(5):380-8.
- Lafeuille MH, Gravel J, Grittner A, Lefebvre P, Ellis L, McKenzie RS. Real-world corticosteroid utilization patterns in patients with metastatic castration-resistant prostate cancer in 2 large US administrative claims databases. *American Health & Drug Benefits*. 2013 Jul;6(6):307-16.
- Mody SH, Huynh L, Zhuo DY, Tran KN, Lefebvre P, Bookhart BK. A cost-analysis model for anticoagulant treatment in the hospital setting. *Journal of Medical Economics*. 2014 Jul;17(7):492-8.
- Lafeuille MH, Grittner AM, Lefebvre P, Ellis L, McKenzie RS, Slaton T, Kozma C. Adherence patterns for abiraterone acetate and concomitant prednisone use in patients with prostate cancer. *Journal of Managed Care and Specialty Pharmacy*. 2014 May;20(5):477-84.
- Laliberté F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P. Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation? *Current Medical Research and Opinion*. 2014 Aug;30(8):1521-8.
- Laliberté F, Coleman CI, Bookhart BK, Lefebvre P, Cloutier M, Damaraju CV, Schein JR, Kaatz S. Weekly risk of venous thromboembolism recurrence in patients receiving oral anticoagulants. *Current Medical Research and Opinion*. 2014 Aug;30(8):1513-20.

- Lafeuille MH, Dean J, Carter V, Duh MS, Fastenau J, Dirani R, Lefebvre P. Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia. *Current Medical Research and Opinion*. 2014 Aug;30(8):1643-55.
- Laliberté F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH, Damaraju CV, Schein JR, Lefebvre P. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. *Current Medical Research and Opinion*. 2014 Jul;30(7):1317-25.
- Lafeuille MH, Dean J, Fastenau J, Panish J, Olson W, Markowitz M, Duh MS, Lefebvre P. Burden of schizophrenia on selected comorbidity costs. *Expert Review of Pharmacoeconomics & Outcomes Research*. 2014 Apr;14(2):259-67.
- Laliberté F, Lefebvre P, Law A, Duh MS, Pocoski J, Lynen R, Darney P. Medicaid spending on contraceptive coverage and pregnancy-related care. *Reproductive Health*. 2014 Mar 3;11(1):20.
- Lafeuille MH, Grittner AM, Gravel J, Bailey RA, Martin S, Garber L, Duh MS, Lefebvre P. Quality measure attainment in patients with type 2 diabetes mellitus. *American Journal of Managed Care*. 2014 Jan;20(1 Suppl):s5-15.
- Duh MS, Hackshaw MD, Ivanova JI, Kruse G, Miller LA, Lefebvre P, Karner P, Wong B. Costs associated with intravenous cancer therapy administration in patients with metastatic soft tissue sarcoma in a US population. *Sarcoma*. 2013;2013:947413.
- Laliberté F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P. Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation? *Current Medical Research and Opinion*. 2014 Apr;30(4):645-53.
- Lafeuille MH, Gravel J, Zhang J, Gorsh B, Figliomeni M, Lefebvre P. Association between consistent omalizumab treatment and asthma control. *The Journal of Allergy and Clinical Immunology*. Pract. 2013 Jan;1(1):51-7.
- Huynh L, McCoy M, Law A, Tran KN, Knuth S, Lefebvre P, Sullivan S, Duh MS. Systematic literature review of the costs of pregnancy in the US. *Pharmacoeconomics*. 2013 Nov;31(11):1005-30.
- Lefebvre P, Coleman CI, Bookhart BK, Wang ST, Mody SH, Tran KN, Zhuo DY, Huynh L, Nutescu EA. Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism. *Journal of Medical Economics*. 2014 Jan;17(1):52-64.
- Viridi NS, Lefebvre P, Parisé H, Duh MS, Pilon D, Laliberté F, Sundaresan D, Garber L, Dirani R. Association of self-monitoring of blood glucose use on glycated hemoglobin and weight in newly diagnosed, insulin-naïve adult patients with type 2 diabetes. *Journal of Diabetes Science and Technology*. 2013 Sep 1;7(5):1229-42.
- Lefebvre P, Laliberté F, Nutescu EA, Duh MS, LaMori J, Bookhart BK, Olson WH, Dea K, Hossou Y, Schein J, Kaatz S. All-cause and disease-related health care costs associated with recurrent venous thromboembolism. *Journal of Thrombosis and Haemostasis*. 2013 Dec;110(6):1288-97.



- Lafeuille MH, Laliberté-Auger F, Lefebvre P, Frois C, Fastenau J, Duh MS. Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis. *BMC Psychiatry*. 2013 Sep 10;13:221.
- Lafeuille MH, Gravel J, Lefebvre P, Fastenau J, Muser E, Doshi D, Duh MS. Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics. *Journal of Medical Economics*. 2013 Nov;16(11):1290-9.
- Laliberté F, Bookhart BK, Nelson WW, Lefebvre P, Schein JR, Rondeau-Leclaire J, Duh MS. Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism. *Patient*. 2013;6(3):213-24.
- Lafeuille MH, Gravel J, Figliomeni M, Zhang J, Lefebvre P. Burden of illness of patients with allergic asthma versus non-allergic asthma. *Journal of Asthma*. 2013 Oct;50(8):900-7.
- Nakabayashi M, Hayes J, Taplin ME, Lefebvre P, Lafeuille MH, Pomerantz M, Sweeney C, Duh MS, Kantoff PW. Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease. *Cancer*. 2013 Aug 15;119(16):2990-8.
- Parisé H, Laliberté F, Lefebvre P, Duh MS, Kim E, Agashivala N, Abouzaid S, Weinstock-Guttman B. Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers. *Journal of the Neurological Sciences*. 2013 Jul 15;330(1-2):71-7.
- Gradman AH, Parisé H, Lefebvre P, Falvey H, Lafeuille MH, Duh MS. Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. *Hypertension*. 2013 Feb;61(2):309-18.
- Manjunath R, Paradis PE, Parisé H, Lafeuille MH, Bowers B, Duh MS, Lefebvre P, Faught E. Burden of uncontrolled epilepsy in patients requiring an emergency room visit or hospitalization. *Neurology*. 2012 Oct 30;79(18):1908-16.
- Laliberté F, Nelson WW, Lefebvre P, Schein JR, Rondeau-Leclaire J, Duh MS. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. *Advances in Therapy*. 2012 Aug;29(8):675-90.
- Lafeuille MH, Dean J, Zhang J, Duh MS, Gorsh B, Lefebvre P. Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma. *Ann Allergy Asthma Immunol*. 2012 Jul;109(1):59-64.
- Lefebvre P, Laliberté F, Nutescu EA, Duh MS, LaMori J, Bookhart BK, Olson WH, Dea K, Schein J, Kaatz S. All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries. *Journal of Managed Care & Specialty Pharmacy*. 2012 Jun;18(5):363-74.
- Jensen JT, Lefebvre P, Laliberté F, Sarda SP, Law A, Pocoski J, Duh MS. Cost burden and treatment patterns associated with management of heavy menstrual bleeding. *Journal of Women's Health (Larchmt)*. 2012 May;21(5):539-47.
- Lafeuille MH, Bailey RA, Vekeman F, McKenzie RS, Lefebvre P. Utilization and cost comparison of erythropoiesis-stimulating agents in inpatient and outpatient hospital settings. *Journal of Medical Economics*. 2012;15(2):352-60.

- Lafeuille MH, Duh MS, Zhang J, Wertz D, Gu T, Swensen A, Lefebvre P. Concomitant asthma medication use in patients receiving omalizumab: results from three large insurance claims databases. *Journal of Asthma*. 2011 Nov;48(9):923-30.
- Laliberté F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. *Menopause*. 2011 Oct;18(10):1052-9.
- Vekeman F, LaMori JC, Laliberté F, Nutescu E, Duh MS, Bookhart BK, Schein J, Dea K, Olson WH, Lefebvre P. In-hospital risk of venous thromboembolism and bleeding and associated costs for patients undergoing total hip or knee arthroplasty. *Journal of Medical Economics*. 2012 02; 15(4): 644-653. doi: 10.3111/13696998.2012.669438.
- Vekeman F, LaMori JC, Laliberté F, Nutescu E, Duh MS, Bookhart BK, Schein J, Dea K, Olson WH, Lefebvre P. Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population. *Journal of Medical Economics*. 2011;14(3):324-34.
- Mease PJ, Zimetbaum PJ, Duh MS, Vekeman F, Guérin A, Boerstoeel-Streefland M, Jiang W, Lefebvre P. Epidemiologic evaluation of cardiovascular risk in patients receiving milnacipran, venlafaxine, or amitriptyline: Evidence from French health data. *Annals of Pharmacotherapy*. 2011 Feb;45(2):179-88.
- Vekeman F, Yameogo ND, Lefebvre P, Bailey RA, McKenzie RS, Piech CT. Healthcare costs associated with nephrology care in pre-dialysis chronic kidney disease patients. *Journal of Medical Economics*. 2010;13(4):673-80.
- Duh MS, Vekeman F, Korves C, Lefebvre P, Dial E, Latremouille-Viau D, Wei RS, Stangle BE, Lafeuille MH, Michna E, Greenberg PE. Risk of hepatotoxicity-related hospitalizations among patients treated with opioid/acetaminophen combination prescription pain medications. *Pain Medicine*. 2010 Nov;11(11):1718-25.
- Scharre DW, Vekeman F, Lefebvre P, Mody-Patel N, Kahler KH, Duh MS. Use of antipsychotic drugs in patients with Alzheimer's disease treated with rivastigmine versus donepezil: a retrospective, parallel-cohort, hypothesis-generating study. *Drugs & Aging*. 2010 Nov 1;27(11):903-13.
- Holloway RW, Grendys EC, Lefebvre P, Vekeman F, McMeekin S. Tolerability, efficacy, and safety of pegylated liposomal Doxorubicin in combination with Carboplatin versus gemcitabine-Carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: a systematic review. *Oncologist*. 2010;15(10):1073-82.
- Lafeuille MH, Bailey RA, Vekeman F, Kilpatrick BS, Senbetta M, Piech CT, Lefebvre P. Drug utilization and cost for erythropoiesis-stimulating agents in a long-term care resident population with chronic kidney disease. *Consult Pharm*. 2010 Aug;25(8):493-500.
- Helmers SL, Paradis PE, Manjunath R, Duh MS, Lafeuille MH, Latrémouille-Viau D, Lefebvre P, Labiner DM. Economic burden associated with the use of generic antiepileptic drugs in the United States. *Epilepsy & Behavior*. 2010 Aug;18(4):437-44.
- Labiner DM, Paradis PE, Manjunath R, Duh MS, Lafeuille MH, Latrémouille-Viau D, Lefebvre P, Helmers SL. Generic antiepileptic drugs and associated medical resource utilization in the United States. *Neurology*. 2010 May 18;74(20):1566-74.

- Lefebvre P, Vekeman F, Cremieux PY. Comment: the impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa. *Annals of Pharmacotherapy*. 2010 Mar;44(3):595; author reply 595-6.
- Laliberté F, Bookhart BK, Corral M, Vekeman F, Duh MS, Bailey RA, Lefebvre P. Impact of anemia on hospitalization rates and costs in a diabetic and a hypertensive cohort of chronic kidney disease patients. *Journal of Managed Care Medicine*. 2009;12(3): 41-50.
- Paradis PE, Latrémouille-Viau D, Moore Y, Mishagina N, Lafeuille MH, Lefebvre P, Gaudig M, Duh MS. Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries. *Current Medical Research and Opinion*. 2009 Jul;25(7):1793-805.
- Lichtenberg FR, Grootendorst P, Van Audenrode M, Latremouille-Viau D, Lefebvre P. The impact of drug vintage on patient survival: a patient-level analysis using Quebec's provincial health plan data. *Value Health*. 2009 Sep;12(6):847-56.
- Laliberté F, Bookhart BK, Vekeman F, Corral M, Duh MS, Bailey RA, Piech CT, Lefebvre P. Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective. *Journal of Managed Care & Specialty Pharmacy*. 2009 May;15(4):312-22.
- Vekeman F, Bookhart BK, White J, McKenzie RS, Duh MS, Piech CT, Lefebvre P. Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin. *Transfusion*. 2009 May;49(5):895-902.
- Parfrey PS, Lauve M, Latremouille-Viau D, Lefebvre P. Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis. *Clinical Journal of the American Society of Nephrology*. 2009 Apr;4(4):755-62.
- Vekeman F, McKenzie RS, Bookhart BK, Laliberté F, Duh MS, Piech CT, Lefebvre P. Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database. *Journal of Medical Economics*. 2009 Mar;12(1):1-8.
- Mundle S, Lefebvre P, Vekeman F, Duh MS, Rastogi R, Moyo V. An assessment of erythroid response to epoetin alfa as a single agent versus in combination with granulocyte- or granulocyte-macrophage colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach. *Cancer*. 2009 Feb 15;115(4):706-15.
- Moyo V, Lefebvre P, Duh MS, Yektashenas B, Mundle S. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. *Annals of Hematology*. 2008 Jul;87(7):527-36.
- LeLorier J, Duh MS, Paradis PE, Lefebvre P, Weiner J, Manjunath R, Sheehy O. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. *Neurology*. 2008 May; 70(22 Pt 2):2179-2186.
- Duh MS, Mody SH, Lefebvre P, Woodman RC, Buteau S, Piech CT. Anaemia and the risk of injurious falls in a community-dwelling elderly population. *Drugs & Aging*. 2008 Apr;25(4):325-34.
- Duh MS, Reynolds Weiner J, Lefebvre P, Neary M, Skarin AT. Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis. *Current Medical Research and Opinion*. 2008 Apr;24(4):967-74.

- LeLorier J, Duh MS, Paradis PE, Latrémouille-Viau D, Lefebvre P, Manjunath R, Sheehy O. Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting. *Current Medical Research and Opinion*. 2008 Apr;24(4):1069-81.
- Duh MS, Weiner JR, White LA, Lefebvre P, Greenberg PE. Management of anaemia: a critical and systematic review of the cost-effectiveness of erythropoiesis-stimulating agents. *Pharmacoeconomics*. 2008; Feb;26(2):99-120. Review.
- Duh MS, Mody SH, Laliberté F, McKenzie RS, Bookhart BK, Lefebvre P. Drug utilization and costs of erythropoietic-stimulating agents in chronic kidney disease patients not receiving dialysis. *Managed Care Interface*. 2007 Dec; 20(12):14-19.
- Vekeman F, McKenzie RS, Lefebvre P, Watson SH, Mody SH, Piech CT, Duh MS. Dose and cost comparison of erythropoietic agents in the inpatient hospital setting. *American Journal of Health-System Pharmacy*. 2007 Sep 15;64(18):1943-9.
- Wu WK, Duh MS, Lefebvre P. Is there a difference in the cost-effectiveness of erythropoietic therapies for the treatment of anemia in patients receiving HCV combination therapy? *Hepatology*. 2007 Jul;46(1):283; author reply 283-4.
- Zilberberg MD, Carter C, Lefebvre P, Raut M, Vekeman F, Duh MS, Shorr AF. Red blood cell transfusions and the risk of acute respiratory distress syndrome among the critically ill: a cohort study. *Crit Care*. 2007;11(3):R63.
- Lefebvre P, Duh MS, Mody SH, Bookhart BK, Piech CT. The economic impact of epoetin alfa therapy on delaying time to dialysis in elderly patients with chronic kidney disease. *Neurodegenerative Disease Management*. 2007 Feb;10(1):37-45.
- Cremieux PY, Van Audenrode M, Lefebvre P. The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease. *Current Medical Research and Opinion*. 2006 Dec;22(12):2329-36. Review.
- Duh MS, Mody SH, McKenzie RS, Lefebvre P, Gosselin A, Bookhart BK, Piech CT. Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations. *Drugs & Aging*. 2006; Dec;23(12):969-76.
- Lefebvre P, Duh MS, Buteau S, Bookhart BK, Mody SH. Medical costs of untreated anemia in elderly patients with pre-dialysis chronic kidney disease. *Journal of the American Society of Nephrology*. 2006 Dec;17(12):3497-502.
- Gosselin A, McKenzie RS, Lefebvre P, Mody SH, Piech CT, Duh MS. Dose conversion ratio between epoetin alfa and darbepoetin alfa in patients with anemia and solid tumors receiving chemotherapy. *Pharmacy and Therapeutics*. 2006 Oct; 31(10):594-603.
- Duh MS, Mody SH, McKenzie RS, Lefebvre P, Gosselin A, Piech CT. Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations. *Clinical Therapeutics*. 2006 Sep;28(9):1443-50.
- Lefebvre P, Vekeman F, Sarokhan B, Enny C, Provenzano R, Cremieux PY. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa. *Current Medical Research and Opinion*. 2006 Oct;22(10):1929-37.

- Lefebvre P, Gosselin A, McKenzie RS, Mody SH, Piech CT, Duh MS. Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations. *Current Medical Research and Opinion*. 2006 Sep;22(9):1623-31.
- Cremieux PY, Vekeman F, Lefebvre P. Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anemia: a Canadian application. *Journal of Oncology Pharmacy Practice*. 2006 Sep;12(3):165-78.
- Chu E, Einhorn LH, Lefebvre P. Clinical benefits of once-weekly epoetin alfa in anemic cancer patients with colorectal cancer receiving chemotherapy. *J Support Oncol*. 2006 May;4(5):243-50.
- Campos SM, Duh MS, Lefebvre P, Rosberg J. Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia. *Journal of the National Comprehensive Cancer Network*. 2005 Nov;3(6):807-16.
- Duh MS, Lefebvre P, Fastenau J, Piech CT, Waltzman RJ. Assessing the clinical benefits of erythropoietic agents using area under the hemoglobin change curve. *Oncologist*. 2005 Jun-Jul;10(6):438-48.
- Van Audenrode M, Fortin P, Havet N, Lefebvre P, Royer J. Estimation des conséquences économiques d'une réduction de la portée de l'article 45 du Code du travail. (Report for l'Ordre des conseillers en ressources humaines et en relations industrielles agréés du Québec) 2003 Nov.
- *Offre de travail au noir et effet de voisinage*, with Fortin B., and Lacroix G., working paper, Université Laval, 2002.